Drug Profile
Research programme: anticancer antibodies - Eurobio Scientific
Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Diaxonhit
- Developer Eurobio Scientific
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in France (Parenteral)
- 03 Sep 2013 Early research in Cancer in France (Parenteral)